

The 22nd Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies

April 29 – May 1, 2022

Friday, April 29, 2022

12:00 pm **Registration Opens**

12:55 pm Welcome and Introductions: Joseph Moore, MD

Session 1: Applying Immunotherapy in Your Clinic Today!

Moderator: H. Kim Lyerly, MD

1:00 pm Pre-session Survey

1:05 pm The Use of Immunotherapy in Breast Cancer
H. Kim Lyerly, MD

1:45 pm The Use of Immunotherapy in Lung Cancer
Scott Antonia, MD

2:25 pm **Break and Product Theater #1**

3:05 pm The Use of Immunotherapy in Colon Cancer
David Hsu, MD, PhD

3:45 pm Immunotherapy Mediated Endocrinopathies in Cancer
Afreen Shariff, MD

4:30 pm **Product Theater #2**

5:00 pm **Reception**

Saturday, April 30, 2022

7:00 – 7:45 am Registration and Breakfast

Session 2: Leukemias / MPNs

Moderator: Harry Erba, MD, PhD

- 7:45 am Welcome and Pre-Session Survey
- 8:00 am **Debate:** Anticoagulant Therapy for Hospitalized Patients with COVID-19: Is More Better?
Thomas Ortel, MD vs. Scott Kaatz, DO, MSc, FACP, SFHM (Wayne State Univ.)
- 8:40 am **Debate:** Oral decitabine Should be Used as Initial Therapy for all Patients with Intermediate and High Risk Myelodysplastic Syndromes?
Guillermo Garcia Manero (MD Anderson) vs. Mikkael Sekeres, MD, MS (U of Miami)
- 9:20 am **Break and Product Theater #3**
- 10:00 am **Debate:** Chronic Phase CML Patients Not Achieving Response Milestones in the First 12 Months of ABL TKI Therapy Should be Switched to asciminib (ABL-001)
Jorge Cortes, MD (Georgia Cancer Center) vs Jerald Radich, MD (Fred Hutch)
- 10:40 am **Debate:** HMA/Venetoclax combinations are now the Treatment of Choice for all Older AML Patients Regardless of Fitness
Eytan Stein, MD (MSKCC) vs. Harry Erba, MD, PhD
- 11:20 am **Debate:** BTK vs BCL2 inhibitors in the relapsed or refractory setting of CLL
Danielle Brander, MD vs. Alan Skarbnik, MD (Novant)
- 12:00 - 1:00 pm Lunch and Time with Exhibitors and Product Theater #4**

Session 3: Lymphomas

Moderator: Danielle Brander, MD

- 1:00 pm Pre-Session Survey
- 1:05 pm **Debate:** The Economics of CAR-T Make it Feasible to Expand to the General Cancer Population as First Salvage
Scott Huntington, MD, MPH, MSc (Yale) vs. Jie Wang, MD
- 1:45 pm **Debate:** BTK Inhibitors Should be First Line Therapy Rather Than Chemotherapy for Waldenstrom's/LPL
Matthew McKinney, MD vs. Alexandra Stefanovic, MD
- 2:25 pm **Break and Product Theater #5**
- 3:05 pm **Debate:** Relapsed Follicular Lymphoma Can Continue to Benefit from Chemoimmunotherapy/ Immunotherapy and Continuous Novel/Targeted Agents Should be Reserved for Later.
Anne Beaven, MD (UNC), vs. Matthew McKinney, MD
- 3:45 pm **How I Treat:** Updates on New Approaches to PNH
Carlos DeCastro, MD
- 4:25 pm Post Session Survey and Adjourn

Sunday, May 1, 2022

7:00am – 7:45am **Registration and Breakfast**

7:45 am Welcome: David Rizzieri, MD

8:00 am Pre-Session Survey

Session 4: Hematology

Moderator: Cristiana Costa Chase, DO

8:10 am **Debate:** Four Drugs Combination is the Standard of Care for Newly Diagnosed Multiple Myeloma
Yubin Kang, MD vs. Cristina Gasparetto, MD

8:50 am **Break and Product Theater #6**

9:30 am Myeloma Case Based Audience Response Session
Cristiana Costa Chase, DO
Panel: Drs. Costa Chase, Gasparetto, and Kang

Is Consolidation Therapy Post Autologous Transplant Needed?
Choosing the Optimal Induction Regimen
What is the role of Immunotherapy/CAR-T in MM

11:15 am Q&A and Post Session Survey

11:30 am Adjourn